Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 193,511 shares of the life sciences company’s stock after selling 3,103 shares during the quarter. Retirement Systems of Alabama owned about 0.12% of Illumina worth $25,236,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Zacks Investment Management purchased a new stake in shares of Illumina in the 3rd quarter valued at about $2,924,000. Freemont Management S.A. acquired a new position in Illumina during the third quarter worth approximately $1,565,000. Weybosset Research & Management LLC lifted its stake in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after acquiring an additional 4,579 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Illumina by 3.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock worth $41,748,000 after acquiring an additional 13,725 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ILMN has been the subject of several research reports. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, November 12th. StockNews.com initiated coverage on shares of Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. Canaccord Genuity Group raised their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $190.00 to $165.00 in a research note on Wednesday. Finally, Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Wednesday, August 28th. Nine investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $165.40.

Illumina Trading Down 1.7 %

Shares of Illumina stock opened at $143.87 on Friday. The company has a 50-day moving average of $144.27 and a two-hundred day moving average of $128.28. The stock has a market cap of $22.82 billion, a PE ratio of -14.44 and a beta of 1.11. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period last year, the business posted $0.33 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.